🔴 Neurosense Therapeutics is trading 5% down today with no new company-specific catalyst identified

Neurosense Therapeutics is trading 5.10% down now at $0.43 after no new company-specific catalyst was identified on August 17, 2026.

• The latest material update was the August 13 CEO letter.
• Financing for the Phase 3 PARAGON ALS study is taking longer than expected, while discussions with strategic partners, investors, and grant providers continue.
• A reverse-split shareholder vote is scheduled for August 26, but neither development directly explains the August 17 decline.